Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06870617 · ClinicalTrials.gov registry record
Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)
A clinical trial of Advanced Cancer and Geriatric Assessment, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 150
- Enrollment target
- 3
- Study locations
NCT06870617 is a study of Advanced Cancer and Geriatric Assessment that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 150 participants, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (39% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06870617, a study of Advanced Cancer and Geriatric Assessment, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
The use of a geriatric assessment to inform oncologic care for older persons with cancer is an evidence-based practice that improves patient-clinician communication, reduces treatment-related toxicity, and is recommended by national guidelines. However, the implementation of a geriatric assessment can be time-consuming and burdensome, leading to suboptimal use in clinical practice. Developed and endorsed by the American Society for Clinical Oncology (ASCO), the Practical Geriatric Assessment (PGA) is designed to improve clinical usability and adoption, but its implementation in real-world settings has not been evaluated. The PACE-70 study aims to evaluate PGA implementation and resultant chemotherapy dose modification among older adults with advanced cancer treated in a community setting. An exploratory aim will evaluate how the PGA, body composition (via abdominal computed tomography scan) and step count monitoring (via FitBit) correlate with chemotherapy toxicity and other clinical outcomes.
Conditions Studied
Interventions
- OTHER Practical Geriatric Assessment
- OTHER Correlation of body composition PGA and step count with outcomes
Study Locations (3)
Pennsylvania
- Lancaster General Hospital - Lancaster
- Pennsylvania Hospital - Philadelphia
New Jersey
- Penn Medicine Princeton Medical Center - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2026-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06870617
The ClinicalTrials.gov registry entry for NCT06870617 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (39% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which Practical Geriatric Assessment is the first listed.
NCT06870617 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06870617 about?
NCT06870617 is a clinical study titled "Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)". The use of a geriatric assessment to inform oncologic care for older persons with cancer is an evidence-based practice that improves patient-clinician communication, reduces treatment-related toxicity, and is recommended by national guidelines. However, the implementation of a geriatric assessment c...
What is the current status of trial NCT06870617?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2025-07-01. Estimated completion is 2026-10-01.
What conditions does trial NCT06870617 study?
This clinical trial studies the following conditions: Advanced Cancer, Geriatric Assessment, Toxicity.
What interventions are being tested in trial NCT06870617?
The interventions under investigation include: Practical Geriatric Assessment (OTHER), Correlation of body composition PGA and step count with outcomes (OTHER).
Who is sponsoring clinical trial NCT06870617?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06870617 being conducted?
This trial has 3 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.